^
BIOMARKER:

HR positive

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
Entrez ID:
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
Zhonghua Yi Xue Za Zhi - 1 week
HR positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A2 - Guideline
Clin Cancer Res - 2 weeks
HR positive
Breast Cancer
SNDX-275
Sensitive: C2 – Inclusion Criteria
BMC Cancer - 2 weeks
HR positive
HER2 Negative Breast Cancer
paclitaxel + cyclophosphamide oral + epirubicin
Sensitive: B - Late Trials
Eur J Cancer - 3 weeks
HR positive
HER2 Negative Breast Cancer
abemaciclib
Sensitive: A1 - Approval
ASCO.org - 3 weeks
HR positive
HER2 Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
ribociclib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
ribociclib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
everolimus
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
olaparib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
letrozole
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
anastrozole
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
talazoparib
Sensitive: A1 - Approval
HR positive
Hormone Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
lapatinib
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
toremifene
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
HER2 inhibitor
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
HER2 inhibitor + Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
Male Breast Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
Male Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
palbociclib
Resistant: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
everolimus
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
fulvestrant
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
letrozole
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
estradiol
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
megestrol
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
Aromatase inhibitor + palbociclib
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
eribulin mesylate
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
exemestane
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
CDK6 inhibitor + Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
CDK4 inhibitor + Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
capecitabine
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
bevacizumab
Sensitive: A2 - Guideline
HR positive
HER2 Negative Breast Cancer
vinorelbine
Sensitive: A2 - Guideline
HR positive
Soft Tissue Sarcoma
GnRH agonist
Sensitive: A2 - Guideline
HR positive
Soft Tissue Sarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
HR positive
Soft Tissue Sarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
Hormone Receptor Positive Breast Cancer
trastuzumab + lapatinib
Resistant: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
trastuzumab
Resistant: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
lapatinib
Resistant: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
PI3K inhibitor
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
DJ 927
Sensitive: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
capecitabine
Sensitive: B - Late Trials
HR positive
HER2 Positive Breast Cancer
trastuzumab + neratinib
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
albumin-bound paclitaxel
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
SNDX-275
Resistant: B - Late Trials
HR positive
HER2 Negative Breast Cancer
capecitabine + DJ 927
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
CDK6 inhibitor
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
CDK4 inhibitor
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
alpelisib
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
chidamide
Sensitive: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
palbociclib + abemaciclib
Sensitive: B - Late Trials
HR positive
Hormone Receptor Positive Breast Cancer
alpelisib
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
SHR6390
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
oral paclitaxel/encequidar
Sensitive: B - Late Trials
HR positive
Breast Cancer
abemaciclib
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
CT7001
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
docetaxel
Sensitive: B - Late Trials
HR positive
HER2 Negative Breast Cancer
ABT-888
Sensitive: B - Late Trials
HR positive
Triple Negative Breast Cancer
olaparib
Sensitive: C1 - Off-label
HR positive
HER2 Negative Breast Cancer
neratinib
Sensitive: C1 - Off-label
HR positive
Hormone Receptor Positive Breast Cancer
abemaciclib
Resistant: C1 - Off-label
HR positive
HER2 Positive Breast Cancer
palbociclib
Sensitive: C1 - Off-label
HR positive
HER2 Negative Breast Cancer
BKM120
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Positive Breast Cancer
carboplatin + gemcitabine
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: C2 – Inclusion Criteria
HR positive
Hormone Receptor Positive Breast Cancer
trastuzumab + neratinib
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Negative Breast Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Negative Breast Cancer
IMP 321
Sensitive: C2 – Inclusion Criteria
HR positive
Hormone Receptor Positive Breast Cancer
enzalutamide
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Negative Breast Cancer
G1T38
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Negative Breast Cancer
tamoxifen
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Positive Breast Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Negative Breast Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
HR positive
Triple Negative Breast Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Negative Breast Cancer
U3-1402
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Negative Breast Cancer
PF-06873600
Sensitive: C2 – Inclusion Criteria
HR positive
HER2 Negative Breast Cancer
everolimus + BI-836845
Sensitive: C3 – Early Trials
HR positive
HER2 Negative Breast Cancer
everolimus + letrozole + leuprolide acetate
Sensitive: C3 – Early Trials
HR positive
HER2 Positive Breast Cancer
palbociclib + tucatinib
Sensitive: C3 – Early Trials
HR positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: C3 – Early Trials
HR positive
Hormone Receptor Positive Breast Cancer
pazopanib
Sensitive: C3 – Early Trials
HR positive
HER2 Negative Breast Cancer
lapatinib
Sensitive: C3 – Early Trials
HR positive
HER2 Negative Breast Cancer
ribociclib + BKM120
Sensitive: C3 – Early Trials
HR positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Resistant: C3 – Early Trials
HR positive
HER2 Negative Breast Cancer
cabozantinib capsule
Sensitive: C3 – Early Trials
HR positive
HER2 Positive Breast Cancer
SYD985
Sensitive: C3 – Early Trials
HR positive
HER2 Negative Breast Cancer
everolimus + abemaciclib
Sensitive: C3 – Early Trials
HR positive
HER2 Negative Breast Cancer
everolimus + ribociclib
Sensitive: C3 – Early Trials